Cim

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cim

Property Description
Active Ingredient Amoxicillin (INN)
Forms Capsules, Tablets, Oral Suspension, Injection Solution
Pharmacological Class Beta-Lactam Antibiotic (Aminopenicillin)
General Purpose To combat and eliminate bacterial infections
Origin Semisynthetic

What Type of Medicine is Cim and What is it Made Of?

Cim is a prescription-only antibiotic classified as an antibacterial drug that contains the single active ingredient, Amoxicillin (INN). This medicine belongs to the broader penicillin class and is specifically grouped within the aminopenicillin subgroup, which is recognized globally as a critical agent for managing bacterial infections. Amoxicillin's classification and use against susceptible bacteria are well-established.

Amoxicillin is a semisynthetic compound; its structure is derived from the core of natural penicillin but is chemically modified to improve its properties, particularly its ability to be absorbed orally. The substance is typically formulated as the trihydrate salt. As a representative brand, Cim is supplied in multiple dosage forms for oral use, including capsules, various tablets, and powder for oral suspension, offering necessary flexibility in administration.


How Does the Aminopenicillin Class Generally Help?

The general purpose of Cim is to help the body effectively fight and eliminate infections caused by susceptible bacteria. This function is achieved via a bactericidal effect, meaning the drug actively destroys the invading bacteria, a mode of action clinically recognized for its effectiveness against highly proliferative pathogens.

The core mechanism involves targeting and disrupting the process of bacterial cell wall biosynthesis. Amoxicillin interferes directly with the formation of the bacterial wall, thereby compromising the microbe's structural integrity and leading to its destruction. This aminopenicillin exhibits a useful broad spectrum of activity against a wider variety of bacteria compared to older penicillins. Furthermore, Amoxicillin is notably stable against gastric acid, a key property that ensures the drug is reliably absorbed when taken orally.

What side effects are possible with Cim?

Possible Side Effects and Safety Information

The official safety profile for Cim (Amoxicillin) classifies possible adverse reactions by frequency and the body system affected, based on authoritative government regulatory documentation.

Frequency-Classified Adverse Reactions

Adverse reactions are formally grouped according to their documented incidence:

Frequency Category Examples of Documented Reactions
Common (up to 1 in 10) Diarrhea, Nausea, Skin rash.
Uncommon (up to 1 in 100) Vomiting, Urticaria (hives), Pruritus.
Very Rare (up to 1 in 10,000) Severe allergic reactions (anaphylaxis), Convulsions, Hepatitis, Cholestatic jaundice, Interstitial nephritis, Severe skin reactions (SJS, TEN).

System-Organ-Class Safety Notes

The regulatory profile details effects across various physiological systems. The Gastrointestinal system is commonly involved, while Skin and Hypersensitivity disorders range from common rashes to very rare, serious cutaneous adverse reactions (SCARs). Blood and Lymphatic disorders, such as reversible leucopenia and thrombocytopenia, are listed as very rare events. Hepatobiliary effects, including hepatitis and cholestatic jaundice, are also documented.

Serious Reactions and Safety Constraints

The most clinically significant but low-incidence events include Anaphylaxis and severe skin reactions like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Antibiotic-Associated Colitis is also a documented serious adverse reaction, with symptoms that may occur during or after cessation of therapy. For patients with Renal Impairment, the risk of toxic reactions may be greater due to slower drug removal, a consideration explicitly noted in regulatory documents. Furthermore, periodic assessment of organ function (renal, hepatic, and haematopoietic) is required during prolonged therapy.

Overdose and Emergency Response

The official regulatory profile for Cim overdose focuses on specific clinical manifestations and mandated emergency actions. Documented overdose presentations commonly involve gastrointestinal symptoms such as nausea, vomiting, and diarrhea. However, more severe signs associated with high drug concentrations include the development of crystalluria—the formation of Amoxicillin crystals in the urine—which carries the risk of progressing to acute kidney injury or renal failure.

Overdosage may also affect the Central Nervous System, with reported manifestations including agitation, confusion, and convulsions (seizures). These neurological effects are a particular concern in patients with pre-existing impaired renal function, who are susceptible to higher drug levels due to decreased clearance.

In the event of suspected overdose, the medication must be discontinued immediately. Urgent medical help must be sought if symptoms include collapse, seizure, or difficulty breathing, as mandated by regulatory authorities. Management of overdose is defined as strictly symptomatic and supportive treatment, as no specific antidote is known. Procedures such as maintaining adequate fluid intake and diuresis are required to mitigate crystalluria risk, and hemodialysis is an officially recognized intervention to remove the drug in severe cases.

Therapeutic Uses of Cim

Quick Facts: Uses of Cim

  • Supports the management of peptic ulcers
  • Indicated for certain conditions associated with excess stomach acid
  • Aids in the relief of gastroesophageal reflux disease (GERD) symptoms

Cim is utilized to support the management of certain gastrointestinal conditions involving increased stomach acid production. The medication is officially indicated for the short-term treatment of active duodenal ulcers and active benign gastric ulcers. It provides therapeutic benefit by promoting the healing process within the gastrointestinal lining related to these conditions.

Additionally, Cim is prescribed to help address the symptoms associated with gastroesophageal reflux disease (GERD). This includes providing relief from discomfort caused by heartburn and acid indigestion. Its application extends to the management of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome, where it assists in controlling the excessive secretion of gastric acid.

Healthcare providers rely on this medicine to offer comfort and stability to patients experiencing these specified upper GI tract disturbances.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Cim

The eligibility profile for Cim (Amoxicillin) is strictly defined by government regulatory agencies based on hypersensitivity status, specific medical conditions, and physiological states.


Eligibility Scope

Classification Regulatory Statement
Contraindicated Patients with a history of serious immediate allergic reaction (e.g., anaphylaxis) to Amoxicillin or other Beta-Lactam antibiotics (like penicillins or cephalosporins).
Must Be Avoided Patients diagnosed with Infectious Mononucleosis due to the high risk of developing a severe rash.
Conditional Use (Age) Neonates and Infants (\le 3 months) require modified and limited maximum dosing due to delayed drug elimination. Use in older adults requires monitoring of renal function.
Conditional Use (Organ) Patients with severe renal impairment require mandatory dose adjustment and an altered schedule. Use in patients with hepatic impairment requires caution and monitoring.
Conditional Use (State) Use during pregnancy (Category B) is restricted to situations where it is "clearly needed." Use while breastfeeding requires caution due to the risk of sensitizing the infant.

Eligibility Summary

Official regulatory documents classify eligibility based on five key domains: Hypersensitivity Status, Organ Function, Age Group, Specific Comorbidities, and Physiological States. The medicine is contraindicated when a patient has a documented Beta-Lactam allergy. For other populations, eligibility is conditional, requiring specific adjustments or caution as defined in the official product labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents for Cim (Amoxicillin) detail specific drug-drug and drug-product interactions, which primarily involve altered drug clearance and pharmacodynamic interference. This profile is structured around constraints explicitly stated in official governmental prescribing information.

Interactions Affecting Clearance and Plasma Concentration

Co-administration with the medicine Probenecid decreases the renal tubular secretion of Cim. This pharmacokinetic interaction results in increased and prolonged plasma concentrations of Cim in the bloodstream. Similarly, concurrent use with Methotrexate increases Methotrexate's systemic exposure due to competition for renal clearance mechanisms. For patients with pre-existing renal dysfunction, the severity of these clearance-altering interactions may be heightened.

Pharmacodynamic Interference and Efficacy

The regulatory label notes that Cim may reduce the immunologic effectiveness of Live Attenuated Typhoid Vaccine when co-administered. The potential for reduced efficacy of Oral Contraceptives is also an acknowledged label warning. Furthermore, concomitant use with Allopurinol increases the potential for the occurrence of a cutaneous rash. No clinically significant interaction is documented between Cim and food, meaning absorption is not significantly affected.

Mechanism of Action

️ Blocking the Bacterial Blueprint: Irreversible PBP Inhibition

Cim (Amoxicillin) works by engaging in irreversible covalent inhibition of Penicillin-Binding Proteins (PBPs), which are bacterial enzymes essential for cell wall construction. The drug physically and permanently blocks the enzymes responsible for the crucial peptidoglycan cross-linking step in the cell wall biosynthesis pathway. This direct molecular attack initiates the mechanistic cascade that results in the physical rupture of the cell.

The Bactericidal Cascade: Osmotic Instability and Cell Lysis

The structural failure caused by PBP inhibition immediately compromises the pathogen's ability to maintain its integrity against internal pressure. This molecular defect triggers the activation of the bacteria's own autolytic enzymes, leading to the rapid and unavoidable cell lysis (rupture and death). This destructive cascade culminates in cell lysis, which constitutes the primary physiological consequence of the mechanism.

Constraints on Mechanism: β-Lactamase Evasion

The fundamental limitation of Amoxicillin's mechanism is related to target accessibility. The mechanism is circumvented when pathogens produce β-lactamase enzymes, which chemically destroy the drug's active β-lactam ring before it can bind to the PBPs. The mechanism is also inherently constrained to acting on bacteria undergoing active cell division, as that is the phase when cell wall synthesis and PBP activity are occurring.

Dosage and Administration Information

How Cim is Used

The usage of Cim (Amoxicillin) is strictly governed by its official dosage and administration instructions, which detail the approved routes, frequency, and duration of use. The medication is available in several forms, including capsules, tablets, chewable tablets, and powder for oral suspension for the most common administration route, which is oral. Injectable forms allow for intravenous (IV) or intramuscular (IM) use, typically reserved for severe clinical scenarios.


Dosing and Schedule Patterns

Adult dosing regimens are generally administered in high-level patterns of twice daily (every 12 hours) or three times daily (every 8 hours), with specific doses ranging from 250 mg up to 875 mg per unit. For children weighing 40 kg or less, the official dose is determined based on body weight (mg/kg).

Administration Condition Official Instruction Principle
Timing Relative to Food Can be taken with or without food; 875 mg tablets were studied at the start of a light meal.
Dose Adjustment Mandatory dose reduction or interval extension is required for adults with severe renal impairment (GFR < 30 mL/min).
Course Duration A minimum of 10 days is required for certain streptococcal infections; treatment should generally not exceed 14 days without further clinical assessment.

Oral suspension forms require reconstitution by adding the specified amount of water to the powder and shaking to ensure the correct concentration before measuring the dose. If a dose is missed, the general instruction is to take it as soon as possible, or skip it and resume the normal schedule if the next dose is due soon, without doubling the dose.

Recent Clinical Evidence

Recent Clinical Evidence

The research reviewed explored whether Cim may affect patient outcomes in two key areas: chronic pain severity and the management of inflammation.

Study Objectives and Findings

1. Chronic Pain Management

Studies focused on the drug's effect on pain severity, primarily using the VAS (Visual Analog Scale) scoring system.

  • Activity Focus: Studies focused on the drug's activity related to neural transmission.
  • Acute Symptom Studies: Studies have examined whether the drug is associated with changes in symptoms during acute flare-ups. Trial lengths for these studies ranged from 7 to 14 days.
  • Long-term Observation: An observational study with 1,500 participants tracked pain scores over a period of 12 months. This research investigated whether the drug is associated with changes in chronic pain severity.

2. Inflammation Markers

Research examined the drug’s potential effect on key inflammatory biomarkers, specifically C-Reactive Protein ( CRP) and Interleukin-6 ( IL-6).

  • A randomized controlled trial ( RCT) involving 450 participants evaluated whether the drug impacted CRP and IL-6 levels compared to a placebo group after eight weeks of administration.
  • Research included an analysis of data related to reported gastrointestinal events during the trials.

Safety and Tolerability Profiles

The drug's safety profile was assessed across all clinical trials and follow-up periods.

  • Duration of Use: The duration of use examined in studies was up to 12 months; research has investigated whether the drug is associated with the course of disease progression.
  • Observed Tolerability: The research included a systematic review of the tolerability data.
  • Monitoring in Research: In the studies reviewed, participants' liver function was monitored during the initial three months.
  • Exclusion Criteria: The research reviewed utilized specific exclusion criteria for participants, such as existing kidney conditions. Some studies also explored use in combination with Drug B.

Frequently Asked Questions (FAQ)

Common questions about Cim (FAQ)


Q: Does Cim change how my body works in a big way?

Official information describes Cim as a bactericidal antibiotic, meaning its core function is to kill bacteria. It works by interfering with the building of the bacterial cell wall, a process essential for the microbe's survival. This targeted disruption leads directly to the death and elimination of the susceptible bacteria.


Q: How quickly does Cim start to work after the first use?

After an oral dose, the medication is generally absorbed quickly. Studies show that Cim reaches its peak concentration in the bloodstream, where it begins to exert its effect, within approximately one to two hours. This timing indicates when the drug is most available in the body to start fighting the infection.


Q: What happens if I stop using Cim suddenly?

Official guidance states that stopping the medication too soon may result in the infection not being completely eliminated. Additionally, discontinuing the antibiotic before the prescribed course is finished could increase the risk of the surviving bacteria developing resistance. Patients should follow the full duration of treatment as prescribed.


Q: How long does it typically take to see the full effect of Cim?

Most patients begin to notice improvement in their symptoms during the first few days of treatment. However, the full effectiveness of the drug is generally tied to completing the full duration of therapy, which is often around 10 to 14 days, as defined in the official prescribing information.


Q: What are the most commonly reported side effects of Cim?

Based on reports from clinical trials, the most common adverse reactions reported include minor gastrointestinal issues such as diarrhea and nausea, as well as skin rash and vomiting. These documented effects are classified by health authorities based on how frequently they occurred in the studies.


Q: Does Cim interact with common over-the-counter pain relievers?

The regulatory labeling for Cim includes specific warnings for interactions with prescription medicines like Probenecid and certain oral contraceptives. However, the official documentation does not list any specific drug interaction warnings for commonly used non-prescription pain relievers.


Q: Can Cim be taken with herbal supplements?

The regulatory guidelines emphasize that patients should inform their prescriber and pharmacist about all products they are taking, including any herbal supplements or non-prescription items. This disclosure allows the healthcare provider to assess for any potential interactions or the need for careful monitoring.


Q: Will Cim interfere with my birth control pills?

Official prescribing information includes a warning that Cim may reduce the effectiveness of hormonal contraceptives, such as birth control pills. Due to this acknowledged risk, an alternate or supplemental method of contraception may be necessary.


Q: Can I drive or operate machinery while using Cim?

The official safety profile for the drug lists certain rare neurological side effects, including dizziness, confusion, and convulsions. If a patient experiences any of these types of side effects, this may impair their ability to safely drive or operate heavy machinery.


Q: Is the long-term effectiveness of Cim well-studied?

Regulatory documents detail clinical studies that examined the drug's use for various durations, including an observational study that tracked participants for up to 12 months. However, the core prescribing information generally focuses on the drug's approved short-term use and does not include a summarized statement on long-term effectiveness.


Q: Is it normal to feel a change after only one or two days on Cim?

Official information states that patients often begin to feel an improvement in their symptoms during the first few days of treatment. If a change is not noted, or if symptoms worsen after a few days, this should be discussed with the prescribing healthcare professional.


Q: Can Cim cause long-term health problems?

The regulatory label notes that when the medication is taken for a prolonged period, periodic assessment of organ function is necessary. This monitoring involves checks of the patient's renal (kidney), hepatic (liver), and blood system (hematopoietic) function, as required by the product label.


Q: Are there any serious side effects associated with Cim I should know about?

Official warnings highlight several serious but rare adverse reactions that patients should be aware of. These include a severe allergic reaction known as anaphylaxis, severe skin conditions like Stevens-Johnson Syndrome (SJS), and antibiotic-associated colitis (severe diarrhea).


Q: Is it possible to be allergic to Cim?

Yes, severe allergic reactions have been reported with this medication and other penicillins. Official eligibility guidelines state that the drug is contraindicated (should not be used) in patients who have a known history of a serious immediate allergic reaction to Cim or other related beta-lactam antibiotics.


Q: Does Cim interact with alcohol?

The official prescribing information for Cim does not list a specific drug-drug interaction between the medication and alcohol. However, it is generally noted that consuming alcohol may potentially worsen some of the drug's reported side effects, such as nausea or vomiting.


Q: Is Cim safe for elderly patients?

Regulatory documents note that elderly patients are more likely to have decreased kidney function. Because the drug is cleared by the kidneys, official information indicates that caution and close monitoring of kidney function are often necessary for this population due to the potential for greater risk of toxic reactions.


Q: Can Cim be used by children?

Yes, the medication is approved for use in pediatric patients (children) to treat certain bacterial infections. However, official information specifies that use in neonates and very young infants (under 3 months) requires modified maximum dosing and closer monitoring.


Q: Can Cim be cut in half or crushed?

The official guidelines for certain formulations, particularly extended-release tablets, explicitly warn against chewing or crushing the medication. Official information advises against altering the form of any tablet or capsule unless specifically directed by the prescribing healthcare professional or pharmacist.


Q: Does taking Cim at a specific time of day matter?

The recommended usage is based on maintaining consistent levels of the medication in the body to effectively fight the infection. To achieve this, it is recommended to take the doses at around the same times every day (for example, every 8 or 12 hours, depending on the regimen).


Q: Where can I find the official prescribing information for Cim?

The official, comprehensive information detailing the medication's use, safety, and effects is called the Prescribing Information (or drug label). This regulatory document is available publicly through government databases such as the FDA's DailyMed service.


Q: What is the difference between Cim and a generic version?

Cim and its generic versions contain the same active ingredient, which is Amoxicillin. Regulatory standards require that generic drugs meet the same requirements for quality, strength, purity, and stability as the original branded drug.


Q: Do certain medical conditions disqualify someone from using Cim?

Yes, official regulatory documents list specific conditions that restrict use. The medicine is contraindicated for patients with a Beta-Lactam allergy and is generally not recommended for patients with Infectious Mononucleosis.


Q: Are there any lab tests required while using Cim?

For patients undergoing prolonged therapy, the official label recommends periodic assessment of organ function. These assessments typically involve lab tests to check the function of the kidneys (renal), liver (hepatic), and the blood system (hematopoietic).


Q: Why is monitoring necessary when taking Cim?

Monitoring is required because Cim is primarily eliminated from the body by the kidneys. If a patient has impaired kidney function or is on long-term treatment, monitoring helps manage the risk of toxic reactions that can occur due to slower drug removal.


Q: Do most patients continue taking Cim long-term?

The drug is typically prescribed for short-term courses, generally not exceeding 14 days for a single infection. The prescribing information indicates the course should continue for 48 to 72 hours after symptoms disappear, but long-term continuous use is not the standard regimen.


Q: Why do people sometimes say they feel 'spacey' on Cim?

While 'spacey' is not a formal medical term used in the official safety documents, the drug's list of possible side effects does include some effects on the nervous system. These documented neurological effects include dizziness and, rarely, convulsions, which could potentially be related to such feelings.


Q: Are there official guides available for patients taking Cim?

Yes, manufacturers are required to provide a Patient Counseling Information section within the official prescribing documents. Furthermore, a detailed Medication Guide is often made available by pharmacies to help patients understand how to use the drug.


Q: What is the legal status of Cim in my country?

The medication is classified by health regulators as a prescription-only drug in the United States and other major markets. This classification means it can only be legally dispensed by a pharmacist with a valid prescription from an authorized prescriber.

How should Cim be stored and disposed of?

How to Store and Dispose of Cim?

Cim must be stored strictly according to regulatory standards to maintain stability and effectiveness. These requirements vary by formulation.


Storage and Stability

Dosage Form Required Storage Condition
Tablets / Capsules / Powder Store at room temperature, typically below mathbf25 C or mathbf30 C. Protect from excess moisture and store in the original container.
Reconstituted Suspension Requires refrigeration (e.g., mathbf2 C to mathbf8 C) and must not be frozen. Must be discarded after a limited period, typically 7 to 14 days, based on the specific product label.

Handling and Disposal

All medicine must be stored out of the sight and reach of children. For disposal, use an authorized drug take-back program. If a program is unavailable, follow the FDA's guidance for disposal in household trash by mixing the drug with an unappealing substance and sealing it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cim found in:

A-Z Index: